What is it about?
In many instances drugs or research compounds are so extensively metabolized in preclinical animals species, that it is not possible to perform in vivo pharmacology studies. Medicinal chemists face the task of re-designing the molecule so that they are resistant to drug metabolism. This can take a lot of time, sometimes it is not possible. The administration of 1-aminobenzotrizole inactivates cytochrome P450 enzymes, which have a dominant role in the metabolism of drugs. Scientists can use the approach to boost the exposure of a compound of interest, enabling proof-of-concept studies for chemical series against a particular drug target.
Featured Image
Why is it important?
This approach can be used to rapidly determine whether a compound series shows efficacy against a given drug target, without investing a large amount of chemistry resource to optimize the compound's pharmacokinetic properties.
Perspectives
The use of 1-aminobenzotriazole in mice is challenging because the compound itself is rapidly eliminated. This provided an opportunity to utilize mini osmotic pumps to provide slow release of the enzyme inhibitor and inhibition of P450 enzymes for up to seven days.
Rowan Stringer
Novartis AG
Read the Original
This page is a summary of: Application of Osmotic Pumps for Sustained Release of 1-Aminobenzotriazole and Inhibition of Cytochrome P450 Enzymes in Mice: Model Comparison with the Hepatic P450 Reductase Null Mouse, Drug Metabolism and Disposition, June 2016, American Society for Pharmacology & Experimental Therapeutics (ASPET),
DOI: 10.1124/dmd.116.070151.
You can read the full text:
Contributors
The following have contributed to this page







